These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8640317)

  • 1. Viral inactivation of blood components: recent advances.
    Horowitz B; Ben-Hur E
    Transfus Clin Biol; 1996; 3(1):75-7. PubMed ID: 8640317
    [No Abstract]   [Full Text] [Related]  

  • 2. Inactivation of pathogens in blood and blood products.
    Ben-Hur E
    Med Health R I; 1998 Dec; 81(12):396-9. PubMed ID: 9884539
    [No Abstract]   [Full Text] [Related]  

  • 3. Pathogen inactivation in cellular blood components: clinical trials and implications of introduction to transfusion medicine.
    AuBuchon JP
    Vox Sang; 2002 Aug; 83 Suppl 1():271-5. PubMed ID: 12617151
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathogen inactivation: emerging indications.
    Kleinman S
    Curr Opin Hematol; 2015 Nov; 22(6):547-53. PubMed ID: 26390164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Viral inactivation of cellular blood products].
    Andreu G
    Nouv Rev Fr Hematol (1978); 1993 Jun; 35(3):215-6. PubMed ID: 8337130
    [No Abstract]   [Full Text] [Related]  

  • 6. Inactivation of viruses found with cellular components.
    Horowitz B; Valinsky J
    Biotechnology; 1991; 19():431-50. PubMed ID: 1786477
    [No Abstract]   [Full Text] [Related]  

  • 7. Viral inactivation and reduction in cellular blood products.
    Friedman LI; Stromberg RR
    Rev Fr Transfus Hemobiol; 1993 Jan; 36(1):83-91. PubMed ID: 8476492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral contamination of blood products.
    Thomas DP
    Lancet; 1994 Jun; 343(8913):1583-4. PubMed ID: 7911913
    [No Abstract]   [Full Text] [Related]  

  • 9. Are inactivation procedures for blood products good or bad?
    Caspari G
    BMJ; 2002 Nov; 325(7372):1116. PubMed ID: 12424183
    [No Abstract]   [Full Text] [Related]  

  • 10. Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma.
    Wagner SJ; Friedman LI; Dodd RY
    Transfus Med Rev; 1991 Jan; 5(1):18-32. PubMed ID: 1802274
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica 2007;92:846-9.
    Gröner A
    Haematologica; 2008 Feb; 93(2):e24-6; author reply e27. PubMed ID: 18245642
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
    Seghatchian J; Hervig T; Putter JS
    Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of 8-methoxypsoralen and long wavelength ultraviolet radiation for decontamination of platelet concentrates.
    Corash L; Lin L; Wiesehahn G
    Blood Cells; 1992; 18(1):57-73; discussion 74. PubMed ID: 1617193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates.
    Corash L
    Vox Sang; 1998; 74 Suppl 2():173-6. PubMed ID: 9704443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prestorage leukocyte depletion of blood products in a closed system.
    Pietersz RN; Steneker I; Reesink HW
    Transfus Med Rev; 1993 Jan; 7(1):17-24. PubMed ID: 8431656
    [No Abstract]   [Full Text] [Related]  

  • 16. [Virus inactivation in blood products].
    Stephan W
    Beitr Infusionsther; 1988; 21():192-201. PubMed ID: 2462975
    [No Abstract]   [Full Text] [Related]  

  • 17. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection.
    Pereira A
    Haematologica; 2007 Jun; 92(6):846-9. PubMed ID: 17550860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Red Cross launches first virus-inactivated blood component.
    Oncology (Williston Park); 1998 Oct; 12(10):1545-6. PubMed ID: 9798207
    [No Abstract]   [Full Text] [Related]  

  • 19. Virus inactivation in blood components by photoactive phenothiazine dyes.
    Wagner SJ
    Transfus Med Rev; 2002 Jan; 16(1):61-6. PubMed ID: 11788930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogen inactivation of labile blood components.
    Prowse C; Robinson AE
    Transfus Med; 2001 Jun; 11(3):147. PubMed ID: 11422944
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.